{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:15:55Z","timestamp":1791476155604,"version":"4.3.4"},"reference-count":89,"publisher":"Bentham Science Publishers Ltd.","issue":"10","funder":[{"DOI":"10.13039\/501100001850","name":"Department of Chemicals and Petrochemicals, Ministry of Chemicals and Fertilizers","doi-asserted-by":"publisher","award":["NIPERR\/Communication\/067"],"award-info":[{"award-number":["NIPERR\/Communication\/067"]}],"id":[{"id":"10.13039\/501100001850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2019,12,27]]},"abstract":"<jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Blood-brain barrier (BBB) provides restrictions for the transportation of various therapeutic\nagents to the brain. Efforts to directly target the brain by olfactory as well as trigeminal nerve pathway,\nbypassing BBB, have grown significantly in recent times. The intranasal route of transportation of the\ndrug encompasses ability for the delivery of drug directly to the brain, improves site-specificity in the\nbrain and avoids systemic side effects. In the current era, novel drug delivery systems are useful tools\nfor targeting the brain without providing any harmful effects in nasal mucosa as well as the central\nnervous system. The complex structure of nasal cavity, mucociliary clearance, degradation by the enzymes\npresent in nasal cavity and pathological conditions like rhinitis, common cold, etc. are the major\ndisputes for nasal drug delivery. The use of nanotechnological approaches like solid lipid nanoparticles,\npolymeric nanoparticles, nanoemulsions, liposomes and polymeric micelles provides the ability to overcome\nthese barriers. There are several emerging nasal drug delivery technologies produced by various\npharmaceutical companies to conquer these hurdles. This review tries to address the recent developments\nin the area of direct drug delivery to the brain through the nasal route.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1567201816666191029122740","type":"journal-article","created":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T09:39:34Z","timestamp":1572341974000},"page":"887-901","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["Drug Delivery and Targeting to the Brain Through Nasal Route: Mechanisms, Applications and Challenges"],"prefix":"10.2174","volume":"16","author":[{"given":"Kanchan","family":"Kashyap","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4864-0133","authenticated-orcid":true,"given":"Rahul","family":"Shukla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.drudis.2017.11.010","volume":"23","author":"Kaushik A.","year":"2018","unstructured":"Kaushik A.; Jayant R.D.; Bhardwaj V.; Nair M.; Personalized nanomedicine for CNS diseases. Drug Discov Today 2018,23(5),1007-1015","journal-title":"Drug Discov Today"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"Agrawal M.","year":"2018","unstructured":"Agrawal M.; Saraf S.; Saraf S.; Antimisiaris S.G.; Chougule M.B.; Shoyele S.A.; Alexander A.; Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 2018,281,139-177","journal-title":"J Control Release"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3389\/fncel.2014.00418","volume":"8","author":"Dubois L.G.","year":"2014","unstructured":"Dubois L.G.; Campanati L.; Righy C.; D\u00e2\u20acAndrea-Meira, I.; Spohr, T.C.L. de S.E; Porto-Carreiro, I.; Pereira, C.M.; Bal\u00c3\u00a7a-Silva, J.; Kahn, S.A.; DosSantos, M.F.; Oliveira, M.de A.; Ximenes-da-Silva, A.; Lopes, M.C.; Faveret, E.; Gasparetto, E.L.; Moura-Neto, V. Gliomas and the vascular fragility of the blood brain barrier. Front Cell Neurosci 2014,8,418","journal-title":"Front Cell Neurosci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"Abbott N.J.","year":"2010","unstructured":"Abbott N.J.; Patabendige A.A.K.; Dolman D.E.M.; Yusof S.R.; Begley D.J.; Structure and function of the blood-brain barrier. Neurobiology of disease 2010,37(1),13-25","journal-title":"Neurobiology of disease"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000321044","author":"Bitter C.","year":"2011","unstructured":"Bitter C.; Suter-Zimmermann K.; Surber C.; Nasal drug delivery in humans. Curr Probl Dermatol 2011,20-35","journal-title":"Curr Probl Dermatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","volume":"195","author":"Crowe T.P.","year":"2018","unstructured":"Crowe T.P.; Greenlee M.H.W.; Kanthasamy A.G.; Hsu W.H.; Mechanism of intranasal drug delivery directly to the brain. Life Sci 2018,195,44-52","journal-title":"Life Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","volume":"11","author":"Illum L.","year":"2000","unstructured":"Illum L.; Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000,11,1-18","journal-title":"Eur J Pharm Sci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0169-409X(93)90015-V","volume":"11","author":"Gizurarson S.","year":"1993","unstructured":"Gizurarson S.; The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev 1993,11(3),329-347","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1211\/0022357011775145","volume":"53","author":"Ugwoke M.I.","year":"2001","unstructured":"Ugwoke M.I.; Verbeke N.; Kinget R.; The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001,53(1),3-21","journal-title":"J Pharm Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1146\/annurev.immunol.25.022106.141634","volume":"25","author":"Iwasaki A.","year":"2007","unstructured":"Iwasaki A.; Mucosal dendritic cells. Annu Rev Immunol 2007,25,381-418","journal-title":"Annu Rev Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"Lochhead J.J.","year":"2012","unstructured":"Lochhead J.J.; Thorne R.G.; Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012,64(7),614-628","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.neuron.2012.03.030","volume":"74","author":"Bergmann O.","year":"2012","unstructured":"Bergmann O.; Liebl J.; Bernard S.; Alkass K.; Yeung M.S.Y.; Steier P.; Kutschera W.; Johnson L.; Land\u00e9n M.; Druid H.; Spalding K.L.; Fris\u00e9n J.; The age of olfactory bulb neurons in humans. Neuron 2012,74(4),634-639","journal-title":"Neuron"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"(Suppl. 6)","DOI":"10.1186\/1471-2202-9-S2-S6","volume":"9","author":"Costantino H.R.","year":"2008","unstructured":"Costantino H.R.; Leonard A.K.; Brandt G.; Johnson P.H.; Quay S.C.; Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci 2008,9(3),(Suppl. 6)","journal-title":"BMC Neurosci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1288\/00005537-198811000-00015","volume":"98","author":"Leopold D.A.","year":"1988","unstructured":"Leopold D.A.; The relationship between nasal anatomy and human olfaction. Laryngoscope 1988,98(11),1232-1238","journal-title":"Laryngoscope"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","volume":"99","author":"Dhuria S.V.","year":"2010","unstructured":"Dhuria S.V.; Hanson L.R.; Frey W.H.; Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci 2010,99(4),1654-1673","journal-title":"J Pharm Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1211\/0022357022539","volume":"56","author":"Illum L.","year":"2004","unstructured":"Illum L.; Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004,56(1),3-17","journal-title":"J Pharm Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","volume":"128","author":"Bourganis V.","year":"2018","unstructured":"Bourganis V.; Kammona O.; Alexopoulos A.; Kiparissides C.; Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm 2018,128,337-362","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1111\/j.2042-7158.2012.01555.x","volume":"64","author":"Renner D.B.","year":"2012","unstructured":"Renner D.B.; Svitak A.L.; Gallus N.J.; Ericson M.E.; Frey W.H.; Hanson L.R.; Intranasal delivery of insulin via the olfactory nerve pathway. J Pharm Pharmacol 2012,64(12),1709-1714","journal-title":"J Pharm Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bcpt.1991.69.4.242","volume":"69","author":"Gottofrey J.","year":"1991","unstructured":"Gottofrey J.; Tjalve H.; Axonal transport of cadmium in the olfactory nerve of the pike. Pharmacol Toxicol 1991,69(4),242-252","journal-title":"Pharmacol Toxicol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"pp 1089-\n1112","DOI":"10.1002\/9781118971758.ch50","author":"Enrique Cometto-Mu\u00f1iz J.","year":"2015","unstructured":"Enrique Cometto-Mu\u00f1iz J.; Simons C.; Trigeminal Chemesthesis.\nIn Handbook of Olfaction and Gustation: 3rd Ed 2015,pp 1089-\n1112","journal-title":"Handbook of Olfaction and Gustation: 3rd Ed"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1021\/mp100029t","volume":"7","author":"Johnson N.J.","year":"2010","unstructured":"Johnson N.J.; Hanson L.R.; Frey W.H.; Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm 2010,7(3),884-893","journal-title":"Mol Pharm"},{"key":"ref=22","first-page":"189","volume":"190","author":"Casettari L.","year":"2014","unstructured":"Casettari L.; Illum L.; Chitosan in nasal delivery systems for therapeutic drugs. J Control Release 2014,190,189-200","journal-title":"J Control Release"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1159\/000445173","volume":"47","author":"Nicholls A.R.","year":"2016","unstructured":"Nicholls A.R.; Holt R.I.G.; Growth hormone and insulin-like growth factor-1. Front Horm Res 2016,47,101-114","journal-title":"Front Horm Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1517\/17425247.2013.790887","volume":"10","author":"Pardeshi C.V.","year":"2013","unstructured":"Pardeshi C.V.; Belgamwar V.S.; Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting. Expert Opin Drug Deliv 2013,10(7),957-972","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","volume":"87","author":"Illum L.","year":"2003","unstructured":"Illum L.; Nasal drug delivery - possibilities, problems and solutions. J Control Release 2003,87(1-3),187-198","journal-title":"J Control Release"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","volume":"11","author":"Illum L.","year":"2000","unstructured":"Illum L.; Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000,11,1-8","journal-title":"Eur J Pharm Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrm1786","volume":"7","author":"Edeling M.A.","year":"2006","unstructured":"Edeling M.A.; Smith C.; Owen D.; Life of a clathrin coat: Insights from Clathrin and AP structures. Nat Rev Mol Cell Biol 2006,7(1),32-44","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0939-6411(01)00149-7","volume":"52","author":"Miyamoto M.","year":"2001","unstructured":"Miyamoto M.; Natsume H.; Iwata S.; Ohtake K.; Yamaguchi M.; Kobayashi D.; Sugibayashi K.; Yamashina M.; Morimoto Y.; Improved nasal absorption of drugs using Poly-L-Arginine: Effects of concentration and molecular weight of Poly-L-Arginine on the nasal absorption of fluorescein Isothiocyanate-Dextran in rats. Eur J Pharm Biopharm 2001,52(1),21-30","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev.physiol.68.040104.131404","volume":"68","author":"Van Itallie C.M.","year":"2006","unstructured":"Van Itallie C.M.; Anderson J.M.; Claudins and epithelial paracellular transport. Annu Rev Physiol 2006,68(1),403-429","journal-title":"Annu Rev Physiol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","volume":"379","author":"Mistry A.","year":"2009","unstructured":"Mistry A.; Stolnik S.; Illum L.; Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009,379(1),146-157","journal-title":"Int J Pharm"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","volume":"69","author":"Gaumet M.","year":"2008","unstructured":"Gaumet M.; Vargas A.; Gurny R.; Delie F.; Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 2008,69(1),1-9","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-37250-6","author":"\u00d6nerci T.M.","year":"2013","unstructured":"\u00d6nerci T.M.;  Nasal Physiology and Pathophysiology of Nasal Disorders 2013","journal-title":"Nasal Physiology and Pathophysiology of Nasal Disorders"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejpb.2015.05.019","volume":"94","author":"Di Gioia S.","year":"2015","unstructured":"Di Gioia S.; Trapani A.; Mandracchia D.; De Giglio E.; Cometa S.; Mangini V.; Arnesano F.; Belgiovine G.; Castellani S.; Pace L.; Lavecchia M.A.; Trapani G.; Conese M.; Puglisi G.; Cassano T.; Intranasal delivery of dopamine to the striatum using glycol chitosan\/sulfobutylether-\u03b2-cyclodextrin based nanoparticles. Eur J Pharm Biopharm 2015,94(1),180-193","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jconrel.2015.01.025","volume":"201","author":"Rassu G.","year":"2015","unstructured":"Rassu G.; Soddu E.; Cossu M.; Brundu A.; Cerri G.; Marchetti N.; Ferraro L.; Regan R.F.; Giunchedi P.; Gavini E.; Dalpiaz A.; Solid microparticles based on chitosan or methyl-\u03b2-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J Control Release 2015,201,68-77","journal-title":"J Control Release"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/ajpa.21523","volume":"145","author":"Noback M.L.","year":"2011","unstructured":"Noback M.L.; Harvati K.; Spoor F.; Climate-related variation of the human nasal cavity. Am J Phys Anthropol 2011,145(4),599-614","journal-title":"Am J Phys Anthropol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0168-3659(01)00389-3","volume":"75","author":"Puttipipatkhachorn S.","year":"2001","unstructured":"Puttipipatkhachorn S.; Nunthanid J.; Yamamoto K.; Peck G.E.; Drug physical state and drug-polymer interaction on drug release from chitosan matrix films. J Control Release 2001,75(1-2),143-153","journal-title":"J Control Release"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1021\/acs.molpharmaceut.5b00088","volume":"12","author":"Mistry A.","year":"2015","unstructured":"Mistry A.; Stolnik S.; Illum L.; Nose-to-brain delivery: Investigation of the transport of nanoparticles with different surface characteristics and sizes in excised porcine olfactory epithelium. Mol Pharm 2015,12(8),2755-2766","journal-title":"Mol Pharm"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1201\/9780203735022","author":"Chang S.F.","year":"2017","unstructured":"Chang S.F.; Chien Y.W.;  In Treatise on Controlled Drug Delivery 2017","journal-title":"In Treatise on Controlled Drug Delivery"},{"key":"ref=39","first-page":"94","volume":"2","author":"Dey S.","year":"2011","unstructured":"Dey S.; Mahanti B.; Mazumder B.; Malgope A.; Sandeepan A.; Dasgupta. Nasal drug delivery: An approach of drug delivery through nasal route. Der Chemica Sinica 2011,2(3),94-106","journal-title":"Der Chemica Sinica"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1517\/13543776.12.3.331","volume":"12","author":"Pezron I.","year":"2004","unstructured":"Pezron I.; Mitra A.K.; Duvvuri S.; Tirucherai G.S.; Prodrug strategies in nasal drug delivery. Expert Opinion on Therapeutic Patents 2004,12(3),331-340","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","author":"Khan A.R.","year":"2017","unstructured":"Khan A.R.; Liu M.; Khan M.W.; Zhai G.; Progress in brain targeting drug delivery system by nasal route. J Control Release 2017,364-389","journal-title":"J Control Release"},{"key":"ref=42","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2004.09.004","author":"Alpar H.O.","year":"2005","unstructured":"Alpar H.O.; Somavarapu S.; Atuah K.N.; Bramwell V.W.; Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev 2005","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0378-5173(96)04817-X","volume":"2","author":"Dua R.","year":"1997","unstructured":"Dua R.; Zia H.; Needham T.; The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits. Int J Pharm 1997,2,233-242","journal-title":"Int J Pharm"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2217\/17435889.2.5.669","author":"Pridgen E.M.","year":"2007","unstructured":"Pridgen E.M.; Langer R.; Farokhzad O.C.; Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine 2007,669-680","journal-title":"Nanomedicine"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jddst.2016.05.003","volume":"35","author":"Warnken Z.N.","year":"2016","unstructured":"Warnken Z.N.; Smyth H.D.C.; Watts A.B.; Weitman S.; Kuhn J.G.; Williams R.O.; Formulation and device design to increase nose to brain drug delivery. J Drug Deliv Sci Technol 2016,35,213-222","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0378-5173(98)00367-6","volume":"178","author":"Soane R.J.","year":"1999","unstructured":"Soane R.J.; Frier M.; Perkins A.C.; Jones N.S.; Davis S.S.; Illum L.; Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999,178(1),55-65","journal-title":"Int J Pharm"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0006-3002(58)90166-5","volume":"29","author":"Smith E.L.","year":"1958","unstructured":"Smith E.L.; Hill R.L.; Borman A.; Activity of insulin degraded by leucine aminopeptidase. Biochim Biophys Acta 1958,29(1),207-208","journal-title":"Biochim Biophys Acta"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0169-409X(89)90018-5","volume":"4","author":"Lee V.H.L.","year":"1989","unstructured":"Lee V.H.L.; Yamamoto A.; Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Deliv Rev 1989,4(2),171-207","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.18433\/J3NC79","volume":"12","author":"Pires A.","year":"2009","unstructured":"Pires A.; Fortuna A.; Alves G.; Falc\u00e3o A.; Intranasal drug delivery: How, why and what for? J Pharm Pharm Sci 2009,12(3),288-311","journal-title":"J Pharm Pharm Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0364-7722(82)80103-3","volume":"6","author":"Bennett D.A.","year":"1982","unstructured":"Bennett D.A.; Lal H.; Discriminative stimulus properties of the vasodilator, hydralazine: Differential generalization with Alpha1 and Alpha2 adrenoreceptor drugs. Prog. Neuro-Psychopharmacol. Biol Psych 1982,6(1),17-26","journal-title":"Biol Psych"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","volume":"29","author":"Marttin E.","year":"1998","unstructured":"Marttin E.; Schipper N.G.M.; Coos Verhoef J.; Merkus F.W.H.M.; Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998,29(1-2),13-38","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-004-9013-3","volume":"22","author":"Graff C.L.","year":"2005","unstructured":"Graff C.L.; Pollack G.M.; Functional evidence for P-Glycoprotein at the nose-brain barrier. Pharm Res 2005,22(1),86-93","journal-title":"Pharm Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ejps.2005.01.009","volume":"24","author":"Westin U.","year":"2005","unstructured":"Westin U.; Piras E.; Jansson B.; Bergstr\u00f6m U.; Dahlin M.; Brittebo E.; Bj\u00f6rk E.; Transfer of Morphine along the Olfactory Pathway to the Central Nervous System after Nasal Administration to Rodents. Eur J Pharm Sci 2005,24(5),565-573","journal-title":"Eur J Pharm Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/PEC.0b013e3180328c92","volume":"23","author":"Holsti M.","year":"2007","unstructured":"Holsti M.; Sill B.L.; Firth S.D.; Filloux F.M.; Joyce S.M.; Furnival R.A.; Prehospital intranasal midazolam for the treatment of pediatric seizures. Pediatr Emerg Care 2007,23(3),148-153","journal-title":"Pediatr Emerg Care"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/molecules14093754","volume":"14","author":"Ozsoy Y.","year":"2009","unstructured":"Ozsoy Y.; Gungor S.; Cevher E.; Nasal Delivery of High Molecular Weight Drugs. Molecules 2009,14(9),3754-3779","journal-title":"Molecules"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.4155\/tde.13.104.Basics","volume":"4","author":"Bruno B.J.","year":"2014","unstructured":"Bruno B.J.; Miller G.D.; Lim C.S.; Basics and recent advances in peptide and protein drug delivery. Therapeutic Delivery 2014,4(11),1443-1467","journal-title":"Therapeutic Delivery"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/med.20086","volume":"4","author":"Juillerat-Jeanneret L.","year":"2007","unstructured":"Juillerat-Jeanneret L.; Schmitt F.; Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: Looking for the grail. Med Res Rev 2007,4,574-590","journal-title":"Med Res Rev"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","volume":"237","author":"Kapoor M.","year":"2016","unstructured":"Kapoor M.; Cloyd J.C.; Siegel R.A.; A review of intranasal formulations for the treatment of seizure emergencies. J Control Release 2016,237,147-159","journal-title":"J Control Release"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","volume":"57","author":"Ugwoke M.I.","year":"2005","unstructured":"Ugwoke M.I.; Agu R.U.; Verbeke N.; Kinget R.; Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv Drug Deliv Rev 2005,57(11),1640-1665","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.drudis.2010.03.011","volume":"15","author":"Duan X.","year":"2010","unstructured":"Duan X.; Mao S.; New strategies to improve the intranasal absorption of insulin. Drug Discov Today 2010,15(11-12),416-427","journal-title":"Drug Discov Today"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrd4363","volume":"13","author":"Mitragotri S.","year":"2014","unstructured":"Mitragotri S.; Burke P.A.; Langer R.; Overcoming the Challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat Rev Drug Discov 2014,13(9),655-672","journal-title":"Nat Rev Drug Discov"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2165\/00003088-200342130-00003","volume":"42","author":"Davis S.S.","year":"2003","unstructured":"Davis S.S.; Illum L.; Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 2003,42(13),1107-1128","journal-title":"Clin Pharmacokinet"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.12691\/ajps-3-5-2","volume":"3","author":"Ghori M.U.","year":"2015","unstructured":"Ghori M.U.; Mahdi A.M.; Smith A.M.; Conway B.R.; Nasal drug delivery systems: An overview. Am J Pharmacol Sci 2015,3(5),110-119","journal-title":"Am J Pharmacol Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejps.2017.09.027","volume":"113","author":"Tiozzo Fasiolo L.","year":"2018","unstructured":"Tiozzo Fasiolo L.; Manniello M.D.; Tratta E.; Buttini F.; Rossi A.; Sonvico F.; Bortolotti F.; Russo P.; Colombo G.; Opportunity and challenges of nasal powders: Drug formulation and delivery. Eur J Pharm 2018,113,2-17","journal-title":"Eur J Pharm"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"628","DOI":"10.2174\/1389200217666160406120509","volume":"17","author":"Oliveira P.","year":"2016","unstructured":"Oliveira P.; Fortuna A.; Alves G.; Falcao A.; Drug-metabolizing enzymes and efflux transporters in nasal epithelium: Influence on the bioavailability of intranasally administered drugs. Curr Drug Metab 2016,17(7),628-647","journal-title":"Curr Drug Metab"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"327-328","DOI":"10.1016\/0168-3659(95)00170-0","volume":"40","author":"Brannon-Peppas L.","year":"1994","unstructured":"Brannon-Peppas L.; Handbook of pharmaceutical excipients:\nWade, A.; Weller, P.J. (Eds.), 2nd Edn., American Pharmaceutical\nAssociation, Washington and The Pharmaceutical Press, London. J Control Release 1994,40(3),327-328","journal-title":"J Control Release"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4155\/tde.11.149","volume":"3","author":"Landis M.S.","year":"2012","unstructured":"Landis M.S.; Boyden T.; Pegg S.; Nasal-to-CNS drug delivery: Where are we now and where are we heading? An industrial perspective. Ther Deliv 2012,3(2),195-208","journal-title":"Ther Deliv"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"69047","DOI":"10.1039\/c5ra06982c","volume":"5","author":"Shukla R.","year":"2015","unstructured":"Shukla R.; Gupta J.; Shukla P.; Dwivedi P.; Tripathi P.; Bhattacharya S.M.; Mishra P.R.; Chitosan coated alginate micro particles for the oral delivery of antifilarial drugs and combinations for intervention in brugia malayi induced lymphatic filariasis. RSC Advances 2015,5(85),69047-69056","journal-title":"RSC Advances"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ejps.2005.04.015","volume":"25","author":"Des Rieux A.","year":"2005","unstructured":"Des Rieux A.; Des Ragnarsson E.G.E.; Gullberg E.; Pr\u00e9at V.; Schneider Y.J.; Artursson P.; Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Eur J Pharm 2005,25(4-5),455-465","journal-title":"Eur J Pharm"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/cancers5031020","volume":"5","author":"van Woensel M.","year":"2013","unstructured":"van Woensel M.; Wauthoz N.; Rosi\u00e8re R.; Amighi K.; Mathieu V.; Lefranc F.; van Gool S.W.; de Vleeschouwer S.; Formulations for intranasal delivery of pharmacological agents to combat brain disease: A new opportunity to tackle gbm? Cancers 2013,5(3),1020-1048","journal-title":"Cancers"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijpharm.2004.05.009","volume":"280","author":"Tafaghodi M.","year":"2004","unstructured":"Tafaghodi M.; Tabassi S.A.S.; Jaafari M.R.; Zakavi S.R.; Momen-Nejad M.; Evaluation of the clearance characteristics of various microspheres in the human nose by Gamma-Scintigraphy. Int J Pharm 2004,280(1-2),125-135","journal-title":"Int J Pharm"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.addr.2009.11.020","volume":"62","author":"Wong H.L.","year":"2010","unstructured":"Wong H.L.; Chattopadhyay N.; Wu X.Y.; Bendayan R.; Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev 2010,62(4-5),503-517","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","volume":"134","author":"Gartziandia O.","year":"2015","unstructured":"Gartziandia O.; Herran E.; Pedraz J.L.; Carro E.; Igartua M.; Hernandez R.M.; Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B Biointerfaces 2015,134,304-313","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2007.06.016","volume":"347","author":"Vyas T.K.","year":"2008","unstructured":"Vyas T.K.; Shahiwala A.; Amiji M.M.; Improved oral bioavailability and brain transport of saquinavir upon administration in novel nanoemulsion formulations. Int J Pharm 2008,347(1-2),93-101","journal-title":"Int J Pharm"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s11095-009-0041-x","volume":"27","author":"Jain R.","year":"2010","unstructured":"Jain R.; Nabar S.; Dandekar P.; Vandana P.; Micellar nanocarriers: Potential nose-to-brain delivery of zolmitriptan as novel migraine therapy. Pharm Res 2010,27(4),655-664","journal-title":"Pharm Res"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1023\/A:1011933410898","volume":"16","author":"Suman J.D.","year":"1999","unstructured":"Suman J.D.; Laube B.L.; Dalby R.; Comparison of nasal deposition and clearance of aerosol generated by a nebulizer and an aqueous spray pump. Pharm Res 1999,16(10),1648-1652","journal-title":"Pharm Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/b978-0-12-815720-6.00007-1","author":"Gorain B.","year":"2019","unstructured":"Gorain B.; Choudhury H.; Pandey M.; Nair A.B.; Iqbal Mohd Amin M.C.; Molugulu N.; Deb P.K.; Tripathi P.K.; Khurana S.; Shukla R.; Kohli K.;  Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer 2019,161-192","journal-title":"Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3109\/03639045.2016.1160110","volume":"42","author":"Pozzoli M.","year":"2016","unstructured":"Pozzoli M.; Rogueda P.; Zhu B.; Smith T.; Young P.M.; Traini D.; Sonvico F.; Dry powder nasal drug delivery: Challenges, opportunities and a study of the commercial teijin puvlizer rhinocort device and formulation. Drug Dev Ind Pharm 2016,42(10),1660-1668","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1517\/17425247.4.6.689","volume":"4","author":"Berger W.E.","year":"2007","unstructured":"Berger W.E.; Godfrey J.W.; Slater A.L.; Intranasal corticosteroids: The development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv 2007,4(6),689-701","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00405-006-0071-5","volume":"263","author":"Merkus P.","year":"2006","unstructured":"Merkus P.; Ebbens F.A.; Muller B.; Fokkens W.J.; Influence of anatomy and head position on intranasal drug deposition. Eur Arch Otorhinolaryngol 2006,263(9),827-832","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0169-409X(97)00067-7","volume":"29","author":"Kublik H.","year":"1998","unstructured":"Kublik H.; Vidgren M.; Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev 1998,29(1),157-177","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","volume":"3","author":"Djupesland P.G.","year":"2013","unstructured":"Djupesland P.G.; Nasal drug delivery devices: Characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res 2013,3(1),42-62","journal-title":"Drug Deliv Transl Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.otohns.2003.07.005","volume":"130","author":"Marple B.","year":"2004","unstructured":"Marple B.; Roland P.; Benninger M.; Safety review of benzalkonium chloride used as a preservative in intranasal solutions: An overview of conflicting data and opinions. Otolaryngol Head Neck Surg 2004,130(1),131-141","journal-title":"Otolaryngol Head Neck Surg"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"S192","DOI":"10.1111\/j.1526-4610.2006.00603.x","volume":"46","author":"Rapoport A.","year":"2006","unstructured":"Rapoport A.; Winner P.; Nasal delivery of antimigraine drugs: Clinical rationale and evidence base. Headache 2006,46(Suppl. 4),S192-S201","journal-title":"Headache"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2500\/aap.2012.33.3565","volume":"33","author":"Hankin C.S.","year":"2012","unstructured":"Hankin C.S.; Cox L.; Lang D.; Bronstone A.; Wang Z.; Lepore M.S.; Buck P.O.; Medical costs and adherence in patients receiving aqueous versus pressurized aerosol formulations of intranasal corticosteroids. Allergy Asthma Proc 2012,33(3),258-264","journal-title":"Allergy Asthma Proc"},{"key":"ref=86","first-page":"78","volume":"104","author":"Heslop K.","year":"2008","unstructured":"Heslop K.; How to use pressurised metered dose inhalers. Nurs Times 2008,104(47),78-80","journal-title":"Nurs Times"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1213\/ANE.0b013e3182239b8c","volume":"113","author":"Hoekman J.D.","year":"2011","unstructured":"Hoekman J.D.; Ho R.J.Y.; Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth Analg 2011,113(3),641-651","journal-title":"Anesth Analg"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jddst.2019.02.013","volume":"51","author":"Gadhave D.","year":"2019","unstructured":"Gadhave D.; Gorain B.; Tagalpallewar A.; Kokare C.; Intranasal teriflunomide microemulsion: An improved chemotherapeutic approach in glioblastoma. J Drug Deliv Sci Technol 2019,51,276-289","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijpharm.2018.03.055","volume":"543","author":"Colombo M.","year":"2018","unstructured":"Colombo M.; Figueir\u00f3 F.; de Fraga Dias A.; Teixeira H.F.; Battastini A.M.O.; Koester L.S.; Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro. Inter Int J Pharm 2018,543(1-2),214-223","journal-title":"Inter Int J Pharm"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T11:02:56Z","timestamp":1579690976000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176280\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,12,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567201816666191029122740","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}